Table 2.
Perceived Utility of Genetic Testing in Specific Clinical Contexts
| Users | Nonusers | |
|---|---|---|
| n | 107 (%) | 42 (%) |
| Clinical Scenarios | ||
| All patients with CKD | 12 (11.2%) | 0 (0%) |
| CKD of unknown etiology | 74 (69.2%) | 16 (38.1%) |
| Specific clinical diagnoses | 80 (74.8%) | 36 (85.7%) |
| Pediatric patients | 27 (25.2%) | 13 (31%) |
| I do not see the value in genetic testing | N/A | 2 (4.8%) |
| Specific Clinical Diagnoses | ||
| Cystic | 74 (69.2%) | 32 (76.2%) |
| Glomerular | 60 (56.1%) | 22 (52.4%) |
| Electrolyte abnormalities | 39 (36.5%) | 20 (47.6%) |
| Tubulointerstitial disease | 38 (35.5%) | 8 (19.1%) |
| Nephrolithiasis | 33 (30.8%) | 9 (21.4%) |
| CAKUT | 29 (27.1%) | 6 (14.3%) |
| Hypertension | 14 (13.1%) | 4 (9.5%) |
| Diabetic nephropathy | 8 (7.5%) | 0 (0.0%) |
| Other (TMA) | 1 (0.9%) | 0 (0.0%) |
Abbreviations: CAKUT, congenital anomalies of the kidney and urinary tract; CKD, chronic kidney disease; N/A, not available; TMA, thrombotic microangiopathy.